本文關(guān)鍵詞： 紫杉醇 卡鉑 卵巢癌 免疫功能 CTL轉(zhuǎn)輸　出處：《現(xiàn)代婦產(chǎn)科進(jìn)展》2015年04期 　論文類(lèi)型：期刊論文

【摘要】：目的:采用荷瘤動(dòng)物模型經(jīng)化療聯(lián)合被動(dòng)免疫治療,初步探討化療免疫"窗口期"對(duì)卵巢癌免疫應(yīng)答的影響及其可能的免疫學(xué)機(jī)制。方法:以荷瘤大鼠為研究對(duì)象,根據(jù)紫杉醇聯(lián)合卡鉑對(duì)荷瘤鼠免疫功能改變的不同時(shí)期給予CTL(cytotoxic T-lymphocyte)主動(dòng)免疫治療。觀察荷瘤體積及機(jī)體免疫微環(huán)境改變。結(jié)果:荷瘤鼠紫杉醇和卡鉑化療后不同時(shí)期給予CTL轉(zhuǎn)輸治療,其中化療后第6天即淋巴細(xì)胞數(shù)最少期,給予免疫治療,腫瘤生長(zhǎng)最緩慢;CT掃描結(jié)果示,化療后6天+免疫治療組的瘤體積最小,且與其余治療組有統(tǒng)計(jì)學(xué)意義。荷瘤鼠免疫功能示,化療后6天+免疫治療組中淋巴細(xì)胞抗原特異性增殖及CD8+T細(xì)胞最明顯,而Treg(T-Lymphocytes,Regulatory)細(xì)胞明顯降低。結(jié)論:紫杉醇和卡鉑聯(lián)合CTL治療腫瘤具有協(xié)同作用,其中化療后6天(即淋巴細(xì)胞降到最低期)是CTL免疫治療的最佳時(shí)間點(diǎn)�；熢斐傻哪[瘤個(gè)體免疫功能的低下或是免疫系統(tǒng)空間的釋放(所謂的免疫"窗口期")為誘導(dǎo)特異性的抗腫瘤免疫應(yīng)答提供了可能,免疫狀態(tài)的檢測(cè)是保證腫瘤患者化療聯(lián)合免疫治療方案治療有效性的重要前提之一。
[Abstract]:Objective: to explore the effect of chemotherapy-immunized "window period" on immune response of ovarian cancer and its possible immunological mechanism by chemotherapy combined with passive immunotherapy. According to the effect of paclitaxel combined with carboplatin on immune function changes in tumor-bearing mice, CTL(cytotoxic T-lymphocyte-based active immunotherapy was given. The tumor volume and immune microenvironment were observed. Results: paclitaxel and carboplatin were treated with paclitaxel and carboplatin at different times after chemotherapy. The patients were given CTL transfusions. On the 6th day after chemotherapy, the least number of lymphocytes was given, and the tumor growth was the slowest. The tumor volume was the smallest in the immunotherapy group on the 6th day after chemotherapy. The immunological function of tumor-bearing mice showed that the lymphocyte antigen specific proliferation and CD8 T cells were the most obvious in the immunotherapy group 6 days after chemotherapy. Conclusion: paclitaxel and carboplatin combined with CTL have synergistic effect in the treatment of tumor. The best time point for CTL immunotherapy is 6 days after chemotherapy (i.e. lymphocytes are reduced to the minimum stage). The immune function of tumor individual caused by chemotherapy or the release of immune system space (so-called immune "window period"). It is possible to induce a specific anti-tumor immune response, The detection of immune state is one of the important prerequisites to ensure the effectiveness of chemotherapy combined with immunotherapy in tumor patients.
【作者單位】： 山西省人民醫(yī)院婦產(chǎn)科;上海交通大學(xué)附屬仁濟(jì)醫(yī)院婦產(chǎn)科;
【基金】：國(guó)家自然基金項(xiàng)目(No:30801363) 山西省自然基金項(xiàng)目(No:2013011045-5)
【分類(lèi)號(hào)】：R737.31

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 馮勤梅;劉萍;吳霞;王穎;狄文;;紫杉醇聯(lián)合卡鉑對(duì)荷瘤鼠細(xì)胞免疫功能影響的研究[J];現(xiàn)代婦產(chǎn)科進(jìn)展;2011年09期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王健;吳愛(ài)東;張紅雁;錢(qián)立庭;;前列腺癌調(diào)強(qiáng)適形放療的臨床療效和副反應(yīng)分析[J];安徽衛(wèi)生職業(yè)技術(shù)學(xué)院學(xué)報(bào);2013年05期

2 白皓;韓寶惠;;手術(shù)在非小細(xì)胞肺癌單發(fā)腦轉(zhuǎn)移治療中的作用分析[J];中國(guó)肺癌雜志;2013年12期

3 許偉;位云艷;譚瑤曦;徐瑋;程雁;吳劍卿;;干細(xì)胞轉(zhuǎn)錄因子Sox2在肺癌中的表達(dá)和意義[J];中國(guó)肺癌雜志;2013年11期

4 白倩;謝琦;彭曉莉;�；�;朱俊東;糜漫天;;二氫楊梅素通過(guò)抑制甲基轉(zhuǎn)移酶誘導(dǎo)人乳腺癌MCF-7細(xì)胞PTEN基因去甲基化[J];第三軍醫(yī)大學(xué)學(xué)報(bào);2014年01期

5 孫多祥;周穎;胡衛(wèi)平;;上皮性卵巢癌生物學(xué)標(biāo)志物的研究進(jìn)展[J];癌癥進(jìn)展;2013年06期

6 Hong Zheng;Jia-Yu Liu;Feng-Ju Song;Ke-Xin Chen;;Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer[J];Cancer Biology & Medicine;2013年03期

7 Shi-Ping Liu;Jia-Xin Yang;Dong-Yan Cao;Keng Shen;;Identification of differentially expressed long non-coding RNAs in human ovarian cancer cells with different metastatic potentials[J];Cancer Biology & Medicine;2013年03期

8 Yang Ke;Liang Ma;Xue-Mei You;Sheng-Xin Huang;Yong-Rong Liang;Bang-De Xiang;Le-Qun Li;;Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy[J];Cancer Biology & Medicine;2013年03期

9 劉芳;唐光才;;乳腺癌影像診斷的研究現(xiàn)狀[J];國(guó)際醫(yī)學(xué)放射學(xué)雜志;2013年06期

10 杜瀟;張思琴;程中;李e，

本文編號(hào)：1508277